Patients with multiple myeloma tumors that featured a three-gene signature demonstrated a higher likelihood of achieving a durable and deep response to selinexor, according to study results published in JCO Precision Oncology.
Selinexor (Xpovio; Karyopharm Therapeutics) is an oral selective inhibitor of nuclear export compound. The drug binds with and inhibits the nuclear export protein XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus.
“Selinexor is an approved therapeutic for patients with relapsed or refractory multiple myeloma. However, not all
